{"id":2046,"date":"2024-11-15T12:03:55","date_gmt":"2024-11-15T12:03:55","guid":{"rendered":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/nous-avons-besoin-des-patients-traites-par-belzutifan-welireg\/"},"modified":"2026-03-31T15:36:29","modified_gmt":"2026-03-31T15:36:29","slug":"belzutifan-welireg-patients-we-need-your-help-2","status":"publish","type":"post","link":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/belzutifan-welireg-patients-we-need-your-help-2\/","title":{"rendered":"Nous avons besoin des patients trait\u00e9s par belzutifan (Welireg)"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_column_text]<\/p>\n<h5>Cancer du rein Canada pr\u00e9pare une soumission aupr\u00e8s de l&rsquo;Agence des m\u00e9dicaments du Canada pour le nouveau traitement belzutifan pour les patients atteints d&rsquo;un carcinome \u00e0 cellules r\u00e9nales (CCR) avanc\u00e9.<\/h5>\n<p>Il s&rsquo;agit d&rsquo;une bonne nouvelle, car les patients ont besoin de nouvelles th\u00e9rapies qui am\u00e9liorent les r\u00e9sultats et r\u00e9pondent \u00e0 des besoins th\u00e9rapeutiques actuellement non satisfaits.<\/p>\n<p>Nous souhaitons conna\u00eetre l&rsquo;avis des patients (ou de leurs aidants) qui ont l&rsquo;exp\u00e9rience de ce traitement (belzutifan\/Welireg). Votre participation \u00e0 cette enqu\u00eate contribuera \u00e0 l&rsquo;\u00e9laboration de la demande d&rsquo;autorisation du m\u00e9dicament en cours d&rsquo;examen.<\/p>\n<p>Il vous faudra 10 \u00e0 15 minutes pour r\u00e9pondre \u00e0 cette enqu\u00eate. Nous vous demandons de r\u00e9pondre \u00e0 l&rsquo;enqu\u00eate avant le 26 novembre 2024.<\/p>\n<p>Si vous avez des questions sur cette enqu\u00eate, \u00e9crivez-nous \u00e0 info@cancerdureincanada.ca et indiquez \u00ab Enqu\u00eate aupr\u00e8s des patients et des aidants\u00bb dans la ligne d&rsquo;objet du courriel.<\/p>\n<p><em><strong>Le lien de l&rsquo;enqu\u00eate est la version en anglais. La version en fran\u00e7ais sera en ligne sur notre site Web \u00e0 partir du mardi 19 novembre.<\/strong><\/em>[\/vc_column_text][vc_empty_space][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/4&Prime;][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/4&Prime;][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/4&Prime;][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/4&Prime;][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text] Cancer du rein Canada pr\u00e9pare une soumission aupr\u00e8s de l&rsquo;Agence des m\u00e9dicaments du Canada pour le nouveau traitement belzutifan pour les patients atteints d&rsquo;un carcinome \u00e0 cellules r\u00e9nales (CCR) avanc\u00e9. Il s&rsquo;agit d&rsquo;une bonne nouvelle, car les patients ont besoin de nouvelles th\u00e9rapies qui am\u00e9liorent les r\u00e9sultats et r\u00e9pondent \u00e0 des besoins th\u00e9rapeutiques actuellement [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2044,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[],"year-of-the-new":[55],"class_list":["post-2046","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-non-classifiee","year-of-the-new-55"],"_links":{"self":[{"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/posts\/2046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/comments?post=2046"}],"version-history":[{"count":1,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/posts\/2046\/revisions"}],"predecessor-version":[{"id":2047,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/posts\/2046\/revisions\/2047"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/media\/2044"}],"wp:attachment":[{"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/media?parent=2046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/categories?post=2046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/tags?post=2046"},{"taxonomy":"year-of-the-new","embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/year-of-the-new?post=2046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}